JP2023537895A5 - - Google Patents

Info

Publication number
JP2023537895A5
JP2023537895A5 JP2023507508A JP2023507508A JP2023537895A5 JP 2023537895 A5 JP2023537895 A5 JP 2023537895A5 JP 2023507508 A JP2023507508 A JP 2023507508A JP 2023507508 A JP2023507508 A JP 2023507508A JP 2023537895 A5 JP2023537895 A5 JP 2023537895A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
composition according
fatty liver
alcoholic fatty
liver disease
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023507508A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023537895A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/KR2021/010780 external-priority patent/WO2022035271A1/ko
Publication of JP2023537895A publication Critical patent/JP2023537895A/ja
Publication of JP2023537895A5 publication Critical patent/JP2023537895A5/ja
Pending legal-status Critical Current

Links

JP2023507508A 2020-08-14 2021-08-13 三重活性体持続型結合体を有効成分として含む薬学組成物 Pending JP2023537895A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
KR10-2020-0102604 2020-08-14
KR20200102604 2020-08-14
PCT/KR2021/010780 WO2022035271A1 (ko) 2020-08-14 2021-08-13 삼중 활성체 지속형 결합체를 유효성분으로 포함하는 약학 조성물

Publications (2)

Publication Number Publication Date
JP2023537895A JP2023537895A (ja) 2023-09-06
JP2023537895A5 true JP2023537895A5 (cg-RX-API-DMAC7.html) 2024-08-20

Family

ID=80247218

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023507508A Pending JP2023537895A (ja) 2020-08-14 2021-08-13 三重活性体持続型結合体を有効成分として含む薬学組成物

Country Status (11)

Country Link
US (1) US20230302148A1 (cg-RX-API-DMAC7.html)
EP (1) EP4197560A4 (cg-RX-API-DMAC7.html)
JP (1) JP2023537895A (cg-RX-API-DMAC7.html)
KR (1) KR20220021890A (cg-RX-API-DMAC7.html)
AU (1) AU2021324792A1 (cg-RX-API-DMAC7.html)
CA (1) CA3187742A1 (cg-RX-API-DMAC7.html)
IL (1) IL299800A (cg-RX-API-DMAC7.html)
MX (1) MX2023001599A (cg-RX-API-DMAC7.html)
TW (1) TW202220700A (cg-RX-API-DMAC7.html)
WO (1) WO2022035271A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA202301081B (cg-RX-API-DMAC7.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022035302A1 (ko) * 2020-08-14 2022-02-17 한미약품 주식회사 글루카곤, glp-1 및 gip 수용체 모두에 활성을 갖는 삼중 활성체를 포함하는 혈압 강하용 약학 조성물
KR20230004135A (ko) * 2021-06-30 2023-01-06 한미약품 주식회사 글루카곤, glp-1 및 gip 수용체 모두에 활성을 갖는 삼중 활성체를 포함하는 조합물의 치료학적 용도

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6096871A (en) 1995-04-14 2000-08-01 Genentech, Inc. Polypeptides altered to contain an epitope from the Fc region of an IgG molecule for increased half-life
CA2249195A1 (en) 1996-03-18 1997-09-25 Board Of Regents, The University Of Texas System Immunoglobin-like domains with increased half lives
RU2013133803A (ru) * 2010-12-22 2015-01-27 Маркадиа Байотек, Инк. Способы лечения метаболических нарушений и ожирения при помощи пептидов на основе глюкагона, активных по отношению к рецепторам гип и гпп
KR102041412B1 (ko) * 2011-12-30 2019-11-11 한미사이언스 주식회사 면역글로불린 Fc 단편 유도체
ES2602486T3 (es) * 2012-06-21 2017-02-21 Indiana University Research And Technology Corporation Análogos de glucagón que muestran actividad de receptor de GIP
AU2014345570B2 (en) * 2013-11-06 2019-01-24 Zealand Pharma A/S Glucagon-GLP-1-GIP triple agonist compounds
JP6712323B2 (ja) * 2015-12-31 2020-06-17 ハンミ ファーマシューティカル カンパニー リミテッド グルカゴン、glp−1及びgip受容体のすべてに活性を有する三重活性体
TWI810937B (zh) * 2017-12-21 2023-08-01 美商美國禮來大藥廠 腸促胰島素(incretin)類似物及其用途
WO2022035302A1 (ko) * 2020-08-14 2022-02-17 한미약품 주식회사 글루카곤, glp-1 및 gip 수용체 모두에 활성을 갖는 삼중 활성체를 포함하는 혈압 강하용 약학 조성물

Similar Documents

Publication Publication Date Title
US10159714B2 (en) Compositions, devices and methods of use thereof for the treatment of cancers
JP4137184B2 (ja) 薬物複合体の製造方法
JP2005523946A5 (cg-RX-API-DMAC7.html)
JP2024532619A5 (cg-RX-API-DMAC7.html)
US7291594B2 (en) GLP-1 derivative and preparation thereof absorbable via mucous membrane
JP2023518260A (ja) アクチビン受容体ii型キメラ及びその使用方法
EP3212217A1 (en) Compositions and peptides having dual glp-1r and glp-2r agonist activity
JP2017538395A5 (cg-RX-API-DMAC7.html)
BG64288B1 (bg) 'ъ''ави на ов 'ля' про'...ин и м...'оди за 'яхно'о пол"-аван...
JP2024540275A5 (cg-RX-API-DMAC7.html)
IL291681B2 (en) Therapeutic use of trigonal glucagon/glp-1/gip receptor agonist or conjugate thereof for liver disease
JP2023551877A5 (cg-RX-API-DMAC7.html)
JP2021514354A5 (cg-RX-API-DMAC7.html)
JP2023502005A5 (cg-RX-API-DMAC7.html)
JP2024544057A5 (cg-RX-API-DMAC7.html)
JP2024178193A (ja) インスリン及びグルカゴンを含む薬学組成物
AU2024276534A1 (en) Treatment of multiple sclerosis with anti-cd40l antibodies
JP2009540842A5 (cg-RX-API-DMAC7.html)
JP2024527220A5 (cg-RX-API-DMAC7.html)
AU2024246525A1 (en) Methods and uses for treating nausea and emesis
JP2022513438A5 (cg-RX-API-DMAC7.html)
WO1999065512A1 (fr) Compositions medicinales contenant des peptides apparentes au facteur de croissance des fibroblastes
JP2024527220A (ja) グルカゴン、glp-1及びgip受容体の全てに対して活性を有する三重活性体を含む組み合わせ物の治療学的用途
CN115531531A (zh) 抗人vegf抗体和化疗联用在制备治疗结直肠癌药物中的用途
RU2025117117A (ru) Фармацевтическая композиция для предупреждения или лечения заболевания "трансплантат против хозяина", содержащая производное GLP-2 или его конъюгат длительного действия